Novartis Pharmaceuticals announced on December 6th that the US Food and Drug Administration (FDA) has approved the launch of its Fabhalta (iptacopan), which is the first FDA approved oral monotherapy for the treatment of adult paroxysmal nocturnal hemoglobinuria (PNH). Phase III clinical trials have shown that this therapy helps to increase patients' hemoglobin levels without the need for blood transfusions. The therapy is expected to be launched in the United States in December.